## Niccolo Riccardi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3806988/publications.pdf

Version: 2024-02-01

		471371		526166
78	1,042	17		27
papers	citations	h-index		g-index
			_ '	
81	81	81		1764
all docs	docs citations	times ranked		citing authors

#	Article	IF	Citations
1	How we deal with Staphylococcus aureus (MSSA, MRSA) central nervous system infections. Frontiers in Bioscience - Scholar, 2022, 14, 1.	0.8	4
2	An octopus gift: Mycobacterium marinum multiple skin lesions. Infection, 2022, 50, 1631-1632.	2.3	5
3	Infections in lung transplanted patients: A review. Pulmonology, 2022, , .	1.0	6
4	Mycobacterium marinum: A brief update for clinical purposes. European Journal of Internal Medicine, 2022, 105, 15-19.	1.0	8
5	Therapeutic Options for Infections Due to vanB Genotype Vancomycin-Resistant Enterococci. Microbial Drug Resistance, 2021, 27, 536-545.	0.9	9
6	Missed opportunities in to clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. Tuberculosis, 2021, 126, 102041.	0.8	1
7	Ultra-short antibiotic prophylaxis guided by preoperative microbiological nasal swabs in endoscopic endonasal skull base surgery. Acta Neurochirurgica, 2021, 163, 369-382.	0.9	12
8	Tuberculosis and pharmacological interactions: A narrative review. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100007.	1.7	11
9	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients―Multi-Centre Observational Study. International Journal of Environmental Research and Public Health. 2021. 18. 340.	1.2	14
10	Injectable Antiretroviral Drugs: Back to the Future. Viruses, 2021, 13, 228.	1.5	7
11	Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. Future Microbiology, 2021, 16, 399-407.	1.0	O
12	Rabies in Europe: An epidemiological and clinical update. European Journal of Internal Medicine, 2021, 88, 15-20.	1.0	9
13	Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. Infectious Diseases and Therapy, 2021, 10, 2479-2488.	1.8	69
14	Flexible cystoscopy for ureteral stent removal without antimicrobial prophylaxis. A prospective observational study. Urologia, 2021, 88, 130-134.	0.3	1
15	The possible impact of SARS-COV-2 on neglected tropical diseases in Europe: the out of spotlights emerging of schistosomiasis. Journal of Preventive Medicine and Hygiene, 2021, 62, E3-E4.	0.9	O
16	Genitourinary Tuberculosis: A Comprehensive Review of a Neglected Manifestation in Low-Endemic Countries. Antibiotics, 2021, 10, 1399.	1.5	5
17	Awareness of European practitioners toward uncommon tropical diseases: are we prepared to deal with mass migration? Results of an international survey. World Journal of Urology, 2020, 38, 1773-1786.	1.2	18
18	Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy. Journal of Travel Medicine, 2020, 27, .	1.4	27

#	Article	IF	CITATIONS
19	A rare case of multi-focal human TB after BCG instillation for non-muscle-invasive bladder cancer. Urologia, 2020, 87, 199-202.	0.3	2
20	Mycobacterium chimaera infections: An update. Journal of Infection and Chemotherapy, 2020, 26, 199-205.	0.8	32
21	Accidental diagnosis of COVID-19 pneumonia after 18F FDG PET/CT: a case series. Clinical and Translational Imaging, 2020, 8, 393-400.	1.1	8
22	Re: Letter to the editor of Public Health in response to  Non-COVID-19 visits to emergency departments during the pandemic: the impact of fear'. Public Health, 2020, 186, 17.	1.4	4
23	<p>Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future</p> . Infection and Drug Resistance, 2020, Volume 13, 2795-2800.	1.1	12
24	Sensitivity, Specificity and Predictive Values of Molecular and Serological Tests for COVID-19: A Longitudinal Study in Emergency Room. Diagnostics, 2020, 10, 669.	1.3	34
25	Non-COVID-19 admissions to the emergency department during the pandemic second wave in Italy: What is changed from the first wave?. American Journal of Emergency Medicine, 2020, 45, 625-626.	0.7	10
26	Non-COVID-19 visits to emergency departments during the pandemic: the impact of fear. Public Health, 2020, 183, 40-41.	1.4	163
27	An outbreak of blister beetle dermatitis in travellers. Journal of Travel Medicine, 2020, 27, .	1.4	4
28	From the past, a long way to future challenges for a greater control of tuberculosis. Tuberculosis, 2020, 123, 101948.	0.8	7
29	COVID-19 pneumonia: increased choline uptake with 18F-choline PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2476-2477.	3.3	8
30	Clofazimine: an old drug for never-ending diseases. Future Microbiology, 2020, 15, 557-566.	1.0	21
31	Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. Journal of Infection, 2020, 80, 536-546.	1.7	38
32	Mould Infections of Traumatic Wounds: A Brief Narrative Review. Infectious Diseases and Therapy, 2020, 9, 1-15.	1.8	25
33	Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: aÂcross-sectional study coordinated by Stop TB Italia Onlus. Public Health, 2020, 180, 17-21.	1.4	13
34	Acute histoplasmosis in travelers: a retrospective study in an Italian referral center for tropical diseases. Pathogens and Global Health, 2020, 114, 40-45.	1.0	7
35	Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3698-3699.	1.3	3
36	HIV and tuberculosis: A historical perspective on conflicts and challenges. Tuberculosis, 2020, 122, 101921.	0.8	16

#	Article	IF	CITATIONS
37	In Reply: The Coronavirus Disease 2019 Global Pandemic: A Neurosurgical Treatment Algorithm. Neurosurgery, 2020, 87, E214-E215.	0.6	10
38	Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia. Lung India, 2020, 37, 455.	0.3	3
39	Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015–2017. BMC Public Health, 2020, 20, 738.	1.2	1
40	Tuberculosis: an ancient disease that remains a medical, social, economical and ethical issue. Journal of Preventive Medicine and Hygiene, 2020, 61, E16-E18.	0.9	4
41	The evolution of a neglected disease: tuberculosis discoveries in the centuries. Journal of Preventive Medicine and Hygiene, 2020, 61, E9-E12.	0.9	2
42	Endoneural abscess of common popliteal nerve as first clinical manifestation of leprosy: the first reported case in history in a low-incidence country. Journal of Preventive Medicine and Hygiene, 2020, 61, E148-E151.	0.9	O
43	Intestinal tuberculosis versus Inflammatory Bowel Diseases: a never-ending challenge. New Microbiologica, 2020, 43, 139-143.	0.1	0
44	SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic. New Microbiologica, 2020, 43, 161-165.	0.1	8
45	Definition of Opportunistic Infections in Immunocompromised Children on the Basis of Etiologies and Clinical Features: A Summary for Practical Purposes. Current Pediatric Reviews, 2019, 15, 197-206.	0.4	18
46	Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. BMC Infectious Diseases, 2019, 19, 564.	1.3	18
47	Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. PLoS ONE, 2019, 14, e0223181.	1.1	22
48	Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. European Journal of Internal Medicine, 2019, 62, 1-6.	1.0	70
49	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. AIDS Reviews, 2019, 20, 75-82.	0.5	2
50	Magnusiomyces clavatus infection in a child after allogeneic hematotopoetic stem cell transplantation: Diagnostic and therapeutic implications. Medical Mycology Case Reports, 2019, 23, 65-67.	0.7	9
51	Is it time to re-think the use of etravirine in patients with available genotypic resistance test?. Infectious Diseases, 2019, 51, 452-455.	1.4	2
52	Neurosurgical treatment of leprosy neuropathy in a low-incidence, European country. Neurological Sciences, 2019, 40, 1371-1375.	0.9	8
53	Towards ending TB: civil community engagement in a rural area of Senegal: results, challenges and future proposal. Infectious Diseases, 2019, 51, 392-394.	1.4	11
54	Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821882165.	0.6	4

#	Article	IF	CITATIONS
55	Rhodococcus defluvii pneumonia. Aids, 2019, 33, 2261-2263.	1.0	5
56	Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. Recent Patents on Anti-infective Drug Discovery, 2019, 13, 190-197.	0.5	2
57	Pseudomonas aeruginosa severe skin infection in a toddler with X-linked agammaglobulinemia due to a novel BTK mutation. Infezioni in Medicina, 2019, 27, 73-76.	0.7	4
58	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. Epidemiology and Infection, 2018, 146, 606-611.	1.0	12
59	From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care. AIDS Research and Human Retroviruses, 2018, 34, 239-240.	0.5	20
60	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. ERJ Open Research, 2018, 4, 00108-2017.	1.1	5
61	Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. AIDS Research and Human Retroviruses, 2018, 34, 168-170.	0.5	1
62	Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clinical Trials, 2018, 19, 242-248.	2.0	14
63	Implementing TB control in a rural, resource-limited setting: the stop-TB Italia project in Senegal. Multidisciplinary Respiratory Medicine, 2018, 13, 41.	0.6	3
64	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. Recent Patents on Anti-infective Drug Discovery, 2018, 13, 3-11.	0.5	18
65	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. Current Hypertension Reviews, 2018, 14, 48-55.	0.5	2
66	A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis. BMC Infectious Diseases, 2018, 18, 431.	1.3	3
67	History of schistosomiasis (bilharziasis) in humans: from Egyptian medical papyri to molecular biology on mummies. Pathogens and Global Health, 2018, 112, 268-273.	1.0	39
68	Salvage Therapy or Simplification of Salvage Regimens with Dolutegravir plus Ritonavir-Boosted Darunavir Dual Therapy in Highly cART-Experienced Subjects: An Italian Cohort. Antiviral Therapy, 2017, 22, 257-262.	0.6	17
69	Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years. AIDS Research and Human Retroviruses, 2017, 33, 19-20.	0.5	0
70	An unexpected waterborne traveller. Infection, 2017, 45, 391-392.	2.3	0
71	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. PLoS ONE, 2017, 12, e0181433.	1.1	9
72	A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48Âweeks' observational data. BMC Infectious Diseases, 2017, 17, 658.	1,3	41

#	Article	IF	CITATIONS
73	Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?. PLoS Neglected Tropical Diseases, 2017, 11, e0005237.	1.3	22
74	A Web Based Tool to Enhance Monitoring and Retention in Care for Tuberculosis Affected Patients. Studies in Health Technology and Informatics, 2017, 237, 204-208.	0.2	2
75	Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection. Clinical Infectious Diseases, 2016, 62, 1323.1-1323.	2.9	2
76	Onychomadesis in a male patient with secondary syphilis. International Journal of STD and AIDS, 2016, 27, 704-705.	0.5	2
77	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. International Journal of Antimicrobial Agents, 2016, 48, 551-554.	1.1	11
78	A pain in the back: anaerobic vertebral spondylitis of hematogenous origin. Infection, 2016, 44, 823-824.	2.3	0